Velcade (bortezomib) 

|

Takeda Oncology and FDA notified healthcare professionals about revisions to the Prescribing Information, pertaining to patients with hepatic impairment at the start of Velcade therapy. The changes also include new safety information on dose adjustment for patients with moderate to severe hepatic impairment.